Drug Trial Radar · NCT01139515
Eletriptan Pharmacokinetics In Korean Males
Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jul 2010
Primary completion
Jul 2010
Study completion Jul 2010
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The hypothesis of this study is that Korean subjects have similar Pharmacokinetics (PK) characteristics to those seen in other populations.
Conditions
- Healthy
Interventions
Eletriptan commercial tabletDrug
20 mg tablet, single dose
Eletriptan commercial tabletDrug
40 mg tablet, single dose of 1 X 40 mg
Eletriptan commercial tabletDrug
40 mg tablet, single dose of 2 X 40 mg
Eletriptan commercial tabletDrug
40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]Time frame: Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose(D)
- AUC From Time Zero to Last Quantifiable Concentration (AUClast)Time frame: Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose (D)
- Maximum Observed Plasma Concentration (Cmax)Time frame: Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose (D)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.